Compile Data Set for Download or QSAR
Report error Found 1332 of ic50 data for polymerid = 400
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227653(US9540377, 23.68 | 3-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.156nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227651(US9540377, 23.66 | US9540377, 23.67 | 6-(5-chlorop...)
Affinity DataIC50: 0.176nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223046(US9540377, 11.10 | 6-{[(1r)-1- cyclobutylethyl]ami...)
Affinity DataIC50: 0.202nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224125(US9540377, 16.44 | 3-{6-[3-chloro-5- (hydroxymethy...)
Affinity DataIC50: 0.205nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224261(US9540377, 17.10 | 3-{8-[(2r)-4-acetyl- 2-phenylpi...)
Affinity DataIC50: 0.215nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227665(US9540377, 23.80 | 5-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.289nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227683(US9540377, 23.98 | 3-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.315nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223705(US9540377, 11.131 | 3-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.344nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227669(US9540377, 23.84 | 5-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.359nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223402(US9540377, 11.14 | 6-{[(1r)-1- cyclobutylethyl]ami...)
Affinity DataIC50: 0.381nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM226428(US9540377, 23.34 | 3-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.424nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227696(US9540377, 23.111 | 2-{1-[6-(5-chloropyridin- 3-yl...)
Affinity DataIC50: 0.435nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227678(US9540377, 23.93 | 3-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.452nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM226426(US9540377, 23.32 | 5-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.453nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224176(US9540377, 16.95 | 5-{6-(5- chloropyridin-3-yl)- 8...)
Affinity DataIC50: 0.494nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224216(US9540377, 16.135 | 3-{6-(5- chloropyridin-3-yl)- ...)
Affinity DataIC50: 0.504nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223681(US9540377, 11.107 | 3-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.507nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227695(US9540377, 23.110 | 2-{1-[6-(5-chloropyridin- 3-yl...)
Affinity DataIC50: 0.515nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224107(US9540377, 16.26 | 3-{6-(5- chloropyridin-3-yl)- 7...)
Affinity DataIC50: 0.517nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM221499(US9540377, 9.31 | 6-{[(1r)-1- cyclobutylethyl]amin...)
Affinity DataIC50: 0.526nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224295(US9540377, 18.21 | 6-{[(1r)-1-cyclobutylethyl]amin...)
Affinity DataIC50: 0.548nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224851(US9540377, 22.62 | US9540377, 22.65 | 3-(6-{[(1r)-...)
Affinity DataIC50: 0.563nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223674(US9540377, 11.100 | 3-{8-[3-(2- chlorophenyl)morph...)
Affinity DataIC50: 0.568nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224214(US9540377, 16.133 | 5-{6-(5- chloropyridin-3-yl)- ...)
Affinity DataIC50: 0.569nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224173(US9540377, 16.92 | 3-{6-(5- chloropyridin-3-yl)- 8...)
Affinity DataIC50: 0.585nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223756(US9540377, 12.18 | 6-{[(1r)-1- cyclobutylethyl]ami...)
Affinity DataIC50: 0.585nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224155(US9540377, 16.74 | 3-{6-(5- chloropyridin-3-yl)- 7...)
Affinity DataIC50: 0.585nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227673(US9540377, 23.88 | 5-{6-(5-chloropyridin-3- yl)-8-...)
Affinity DataIC50: 0.598nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224239(US9540377, 16.158 | 3-{6-(5-chloro-2- methylpyridi...)
Affinity DataIC50: 0.601nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224288(US9540377, 18.14 | 5-(6-(5-chloropyridin-3-yl)-7-(...)
Affinity DataIC50: 0.620nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227658(US9540377, 23.73 | 5-{8-[1-(3-chloro-2- fluorophen...)
Affinity DataIC50: 0.623nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223200(US9540377, 11.11 | 3-(6-{[(1r)-1- cyclobutylethyl]...)
Affinity DataIC50: 0.626nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223702(US9540377, 11.128 | 3-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.642nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224146(US9540377, 16.65 | US9540377, 16.66 | 3-{6-(3- chl...)
Affinity DataIC50: 0.658nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224323(US9540377, 18.49 | 3-{6-(5-chloropyridin-3-yl)-7-[...)
Affinity DataIC50: 0.670nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227671(US9540377, 23.86 | US9540377, 23.87 | 5-{6-(5-chlo...)
Affinity DataIC50: 0.675nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224103(US9540377, 16.22 | 6-(3-chlorophenyl)-7- [(trans-4...)
Affinity DataIC50: 0.680nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224240(US9540377, 16.159 | 5-{6-(5-chloro-2- methylpyridi...)
Affinity DataIC50: 0.704nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM227694(US9540377, 23.109 | 2-{[6-(5-chloropyridin-3- yl)-...)
Affinity DataIC50: 0.707nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM221505(US9540377, 9.39 | 6-{[(1r)-1- cyclobutylethyl]amin...)
Affinity DataIC50: 0.753nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224650(US9540377, 19.1 | 3-[6-{[(1r)-1- cyclobutylethyl]a...)
Affinity DataIC50: 0.763nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223736(US9540377, 11.165 | 3-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.767nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223714(US9540377, 11.142 | 3-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.774nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223703(US9540377, 11.129 | 3-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.788nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223737(US9540377, 11.166 | 5-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.790nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223669(US9540377, 11.95 | US9540377, 11.96 | 3-[6-{[(1r)-...)
Affinity DataIC50: 0.791nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224116(US9540377, 16.35 | 5-{6-(5- chloropyridin-3-yl)- 7...)
Affinity DataIC50: 0.824nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224187(US9540377, 16.106 | 5-{6-(5- chloropyridin-3-yl)- ...)
Affinity DataIC50: 0.825nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM223712(US9540377, 11.140 | 5-(6-{[(1r)-1- cyclobutylethyl...)
Affinity DataIC50: 0.841nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM224243(US9540377, 16.162 | 3-{6-(5-chloro-2- hydroxypyrid...)
Affinity DataIC50: 0.847nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

Displayed 1 to 50 (of 1332 total ) | Next | Last >>
Jump to: